Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

Merck & Co reorganises its HCP communities, hands Univadis to Physicians Interactive

Physicians Interactive outlines globalambitions for its newly-expanded network

- PMLiVE

Leo Pharma’s Enstilar approved by FDA

Topical psoriasistreatment given the green light

- PMLiVE

Can medical technology afford market access?

Medical technologies should be innovative, unique, and have technical feasibility and robust intellectual property. This does not, however, guarantee successful market access and reimbursement.

- PMLiVE

BPL bags FDA approval for rare bleeding disorder therapy

First drug approved for hereditary Factor X deficiency

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

- PMLiVE

Steve Arlington joins Pistoia Alliance

Former PwC partner takes up role as the innovationnon-profit's president

- PMLiVE

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives

- PMLiVE

Ashley Communications appoints new director

Philippa Moody joins from Boehringer Ingelheim

- PMLiVE

Crescendo Biologics appoints Peter Pack as CEO

Launches new strategy in oncology R&D

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

- PMLiVE

Sidestep into Crohn’s could help Stelara cope with new competition

Filing for new indication expected before year's end

Daiichi Sankyo logo

Daiichi Sankyo cuts a swathe through US workforce

Plans to shed upto 1,200 jobs across the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links